Spark Therapeutics, Inc. Forecasted to Earn FY2017 Earnings of ($7.84) Per Share (ONCE)

Spark Therapeutics, Inc. (NASDAQ:ONCE) – Equities researchers at Cantor Fitzgerald reduced their FY2017 earnings per share estimates for shares of Spark Therapeutics in a research note issued on Tuesday. Cantor Fitzgerald analyst E. Piros now expects that the biotechnology company will earn ($7.84) per share for the year, down from their prior forecast of ($6.77). Cantor Fitzgerald has a “Buy” rating and a $94.00 price objective on the stock. Cantor Fitzgerald also issued estimates for Spark Therapeutics’ FY2018 earnings at ($6.56) EPS.

Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.75) by $0.14. Spark Therapeutics had a negative return on equity of 59.74% and a negative net margin of 962.72%. The company had revenue of $1.48 million for the quarter, compared to the consensus estimate of $1.33 million. During the same quarter last year, the business earned ($1.04) earnings per share. Spark Therapeutics’s revenue was up 14.7% compared to the same quarter last year.

ILLEGAL ACTIVITY NOTICE: “Spark Therapeutics, Inc. Forecasted to Earn FY2017 Earnings of ($7.84) Per Share (ONCE)” was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://sportsperspectives.com/2017/08/10/spark-therapeutics-inc-forecasted-to-earn-fy2017-earnings-of-7-84-per-share-once.html.

A number of other equities research analysts have also weighed in on the company. Zacks Investment Research lowered Spark Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, May 11th. William Blair assumed coverage on Spark Therapeutics in a research report on Wednesday, June 28th. They set an “outperform” rating for the company. Jefferies Group LLC reaffirmed a “hold” rating and set a $59.00 price target on shares of Spark Therapeutics in a research report on Wednesday, April 26th. BidaskClub raised Spark Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Finally, ValuEngine lowered Spark Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 20th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and twelve have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $82.27.

Shares of Spark Therapeutics (NASDAQ:ONCE) opened at 76.69 on Thursday. The firm’s market cap is $2.37 billion. Spark Therapeutics has a 1-year low of $35.07 and a 1-year high of $80.89. The company’s 50-day moving average price is $66.46 and its 200 day moving average price is $59.61.

In related news, CFO Stephen W. Webster sold 2,337 shares of the firm’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $71.12, for a total value of $166,207.44. Following the transaction, the chief financial officer now directly owns 4,837 shares of the company’s stock, valued at approximately $344,007.44. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Jeffrey D. Marrazzo sold 28,650 shares of the firm’s stock in a transaction dated Wednesday, August 2nd. The shares were sold at an average price of $80.01, for a total value of $2,292,286.50. Following the sale, the chief executive officer now directly owns 258,650 shares in the company, valued at $20,694,586.50. The disclosure for this sale can be found here. Insiders have sold a total of 314,310 shares of company stock worth $21,866,838 over the last three months. Insiders own 7.30% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. American International Group Inc. boosted its stake in Spark Therapeutics by 17.4% in the first quarter. American International Group Inc. now owns 11,582 shares of the biotechnology company’s stock worth $618,000 after buying an additional 1,714 shares in the last quarter. Victory Capital Management Inc. boosted its stake in Spark Therapeutics by 11.4% in the first quarter. Victory Capital Management Inc. now owns 412,660 shares of the biotechnology company’s stock worth $22,011,000 after buying an additional 42,388 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Spark Therapeutics by 7.8% in the first quarter. JPMorgan Chase & Co. now owns 1,549,093 shares of the biotechnology company’s stock worth $82,628,000 after buying an additional 112,596 shares in the last quarter. TD Asset Management Inc. boosted its stake in Spark Therapeutics by 4.5% in the first quarter. TD Asset Management Inc. now owns 76,451 shares of the biotechnology company’s stock worth $4,078,000 after buying an additional 3,300 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Spark Therapeutics by 10.9% in the first quarter. Bank of New York Mellon Corp now owns 111,043 shares of the biotechnology company’s stock worth $5,923,000 after buying an additional 10,916 shares in the last quarter. 88.95% of the stock is currently owned by institutional investors and hedge funds.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply